TRCT
CUE icon

Tower Research Capital (TRC)’s Cue Biopharma CUE Stock Holding History

Tower Research Capital (TRC)’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.4K Buy
+869
New +$19.6K ﹤0.01% 3278
2025
Q4 		– Sell
-338
Closed -$7.28K – 5216
2025
Q3 		$7.28K Buy
+338
New +$7.93K ﹤0.01% 4105
2025
Q2 		– Sell
-129
Closed -$3.53K – 5302
2025
Q1 		$3.53K Sell
129
-222
-63% -$8.24K ﹤0.01% 4394
2024
Q4 		$11.5K Buy
351
+110
+46% +$4.13K ﹤0.01% 3706
2024
Q3 		$5.46K Sell
241
-138
-36% -$2.99K ﹤0.01% 4267
2024
Q2 		$14.1K Buy
379
+270
+248% +$13.4K ﹤0.01% 3963
2024
Q1 		$6.18K Sell
109
-54
-33% -$3.81K ﹤0.01% 4418
2023
Q4 		$12.9K Sell
163
-21
-11% -$1.5K ﹤0.01% 4002
2023
Q3 		$12.7K Buy
184
+90
+96% +$8.79K ﹤0.01% 3870
2023
Q2 		$10.3K Buy
+94
New +$11K ﹤0.01% 4141
2022
Q4 		– Sell
-97
Closed -$6K – 5951
2022
Q3 		$6K Sell
97
-87
-47% -$7.48K ﹤0.01% 5000
2022
Q2 		$13K Buy
184
+75
+69% +$8.77K ﹤0.01% 4199
2022
Q1 		$16K Buy
109
+30
+38% +$6.36K ﹤0.01% 3745
2021
Q4 		$27K Sell
79
-14
-15% -$5.41K ﹤0.01% 3337
2021
Q3 		$41K Sell
93
-78
-46% -$27.2K ﹤0.01% 3110
2021
Q2 		$60K Buy
171
+128
+298% +$49.6K ﹤0.01% 2875
2021
Q1 		$16K Sell
43
-69
-62% -$28.4K ﹤0.01% 4046
2020
Q4 		$42K Buy
112
+73
+187% +$29.2K ﹤0.01% 3274
2020
Q3 		$18K Sell
39
-216
-85% -$124K ﹤0.01% 3895
2020
Q2 		$188K Buy
+255
New +$185K 0.01% 1838
2019
Q4 		– Sell
-17
Closed -$4K – 3665
2019
Q3 		$4K Buy
+17
New +$4.08K ﹤0.01% 3398
2019
Q2 		– Sell
-69
Closed -$16K – 3778
2019
Q1 		$16K Sell
69
-652
-90% -$124K ﹤0.01% 2392
2018
Q4 		$102K Buy
721
+585
+430% +$106K 0.01% 952
2018
Q3 		$37K Buy
136
+125
+1,136% +$36.1K ﹤0.01% 1948
2018
Q2 		$4K Sell
11
-3
-21% -$1.19K ﹤0.01% 3118
2018
Q1 		$6K Buy
+14
New +$6.38K ﹤0.01% 2649

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

Tower Research Capital (TRC)'s CUE Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Cue Biopharma (CUE) in Q2 2026: 869 shares worth $27.4K. The stake represents ﹤0.01% of the portfolio and ranks #3278 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in CUE as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in CUE in Q1 2018 and has held it in 26 quarters since. The position peaked at $188K in Q2 2020. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Tower Research Capital (TRC) held 869 shares of Cue Biopharma worth $27.4K as of Q2 2026.
  • Cue Biopharma was a new Tower Research Capital (TRC) position in Q2 2026.
  • Cue Biopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3278 holding.
  • Tower Research Capital (TRC) first reported a position in Cue Biopharma in Q1 2018 and has held it in 26 quarters since.
  • Tower Research Capital (TRC)'s Cue Biopharma position peaked at $188K in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.